The mRNA drug developer Moderna Therapeutics has closed yet another gargantuan round of funding. The $474 million in equity financing brings its total cash on hand to $1.4 billion. The money will be used to invest in its mRNA technology and support its growing clinical pipeline—two studies have begun and two more are near. Moderna also plans to build a $100 million manufacturing facility outside Boston to support the clinical trials. The biotech says it will unveil more details this fall.